MINIMAL REQUIREMENTS FOR THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 V3 DOMAIN TO SUPPORT THE SYNCYTIUM-INDUCING PHENOTYPE - ANALYSIS BY SINGLE AMINO-ACID SUBSTITUTION

被引:460
|
作者
DEJONG, JJ
DERONDE, A
KEULEN, W
TERSMETTE, M
GOUDSMIT, J
机构
[1] UNIV AMSTERDAM,DEPT VIROL,AMSTERDAM,NETHERLANDS
[2] NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,AMSTERDAM,NETHERLANDS
[3] UNIV UTRECHT,INST VIROL,UTRECHT,NETHERLANDS
关键词
D O I
10.1128/JVI.66.11.6777-6780.1992
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The third variable domain (V3) of the human immunodeficiency virus type 1 external envelope contains determinants of cell tropism, cytopathicity, and infectivity and elicits antibodies able to block infectivity in vitro and in vivo. Our study encompassed point-mutational analysis of HXB-2 viruses containing patient-derived V3 regions and expressing a non-syncytium-inducing, low-replicating phenotype in T-cell line SupT1. The mutation within V3 of a serine at position 306 into an also naturally occurring arginine (S to R) required an additional, naturally occurring mutation at position 320 (aspartate to glutamine, D to Q) or 324 (aspartate to asparagine, D to N) for full expression of the syncytium-inducing, high-replicating (SI) phenotype. The naturally occurring mutation of an aspartate into an arginine at position 320 (D to R) was sufficient for production of the SI phenotype. This study proves that introduction of a positively charged amino acid at position 306 or 320, previously shown to be strongly associated with the SI phenotype in field isolates (R. A. M. Fouchier, M. Groenink, N. A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker, J. Virol. 66:3183-3187, 1992), is minimally required for production of SI viruses. In addition, naturally occurring mutations at residue 324 also modulate the virus phenotype.
引用
收藏
页码:6777 / 6780
页数:4
相关论文
共 50 条
  • [1] SIMPLE DETERMINATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNCYTIUM-INDUCING V3 GENOTYPE BY PCR
    FOUCHIER, RAM
    BROUWER, M
    BROERSEN, SM
    SCHUITEMAKER, H
    JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (04) : 906 - 911
  • [2] QUANTITATIVE-ANALYSIS OF SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING VIRUS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SHAFER, RW
    AGUINIGA, E
    MERIGAN, TC
    JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (01) : 212 - 214
  • [3] INFECTIOUS VIRUS TITER, REPLICATIVE AND SYNCYTIUM-INDUCING CAPACITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    NKENGASONG, JN
    PEETERS, M
    NYS, P
    WILLEMS, B
    PIOT, P
    VANDERGROEN, G
    JOURNAL OF MEDICAL VIROLOGY, 1995, 45 (01) : 78 - 81
  • [4] EFFECT OF A SINGLE AMINO-ACID SUBSTITUTION IN THE V3 DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - GENERATION OF REVERTANT VIRUSES TO OVERCOME DEFECTS IN INFECTIVITY IN SPECIFIC CELL-TYPES
    MORRIS, JF
    STERNBERG, EJ
    GUTSHALL, L
    PETTEWAY, SR
    IVANOFF, LA
    JOURNAL OF VIROLOGY, 1994, 68 (12) : 8380 - 8385
  • [5] STANDARDIZED MICROTITER ASSAY FOR DETERMINATION OF SYNCYTIUM-INDUCING PHENOTYPES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES
    JAPOUR, AJ
    FISCUS, SA
    ARDUINO, JM
    MAYERS, DL
    REICHELDERFER, PS
    KURITZKES, DR
    JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (09) : 2291 - 2294
  • [6] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CLONES CHIMERIC FOR THE ENVELOPE V3 DOMAIN DIFFER IN SYNCYTIUM FORMATION AND REPLICATION CAPACITY
    DEJONG, JJ
    GOUDSMIT, J
    KEULEN, W
    KLAVER, B
    KRONE, W
    TERSMETTE, M
    DERONDE, A
    JOURNAL OF VIROLOGY, 1992, 66 (02) : 757 - 765
  • [7] SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING CAPACITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SUBTYPES OTHER THAN B - PHENOTYPIC AND GENOTYPIC CHARACTERISTICS
    DEWOLF, F
    HOGERVORST, E
    GOUDSMIT, J
    FENYO, EM
    RUBSAMENWAIGMANN, H
    HOLMES, H
    GALVAOCASTRO, B
    KARITA, E
    WASI, C
    SEMPALA, SDK
    BAAN, E
    ZORGDRAGER, F
    LUKASHOV, V
    OSMANOV, S
    KUIKEN, C
    CORNELISSEN, M
    BELSEY, EM
    HEYWARD, W
    ESPARZA, J
    VANDEPERRE, P
    SEMPALA, S
    TUGUME, B
    BIRYAHWAHO, B
    VONBRIESEN, H
    ESSER, R
    GREZ, M
    NEWBERRY, A
    RANJBAR, S
    TOMLINSON, P
    BRADAC, J
    MCCUTCHAN, F
    LOUWAGIE, J
    HEGERICH, P
    LOPEZGALINDEZ, C
    OLIVARES, I
    DOPAZO, J
    MULLINS, JI
    DELWART, EL
    BACHMANN, HM
    HAHN, BH
    GAO, F
    YUE, L
    SARAGOSTI, S
    SCHOCHETMAN, G
    KALISH, M
    LUO, CC
    GEORGE, R
    PAU, CP
    WEBER, J
    CHEINGSONGPOPOV, R
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) : 1387 - 1400
  • [8] Importance of method in the determination of syncytium-inducing phenotype of human immunodeficiency virus type 1 clinical isolates
    Liesnard, C
    Delforge, ML
    Tchetcheroff, M
    DeMaertelaer, V
    Farber, CM
    VanVooren, JP
    JOURNAL OF VIROLOGICAL METHODS, 1997, 64 (02) : 137 - 145
  • [9] A SINGLE AMINO-ACID SUBSTITUTION IN THE V1 LOOP OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 ALTERS CELLULAR TROPISM
    BOYD, MT
    SIMPSON, GR
    CANN, AJ
    JOHNSON, MA
    WEISS, RA
    JOURNAL OF VIROLOGY, 1993, 67 (06) : 3649 - 3652
  • [10] CHARACTERIZATION OF A V3 DOMAIN-SPECIFIC NEUTRALIZING HUMAN MONOCLONAL-ANTIBODY THAT PREFERENTIALLY RECOGNIZES NON-SYNCYTIUM-INDUCING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS
    SCHUTTEN, M
    LANGEDIJK, JPM
    ANDEWEG, AC
    HUISMAN, RC
    MELOEN, RH
    OSTERHAUS, ADME
    JOURNAL OF GENERAL VIROLOGY, 1995, 76 : 1665 - 1673